全文获取类型
收费全文 | 178766篇 |
免费 | 14669篇 |
国内免费 | 7672篇 |
专业分类
耳鼻咽喉 | 1167篇 |
儿科学 | 4940篇 |
妇产科学 | 3966篇 |
基础医学 | 24827篇 |
口腔科学 | 3820篇 |
临床医学 | 14396篇 |
内科学 | 27643篇 |
皮肤病学 | 2663篇 |
神经病学 | 18481篇 |
特种医学 | 2988篇 |
外国民族医学 | 47篇 |
外科学 | 13566篇 |
综合类 | 25808篇 |
现状与发展 | 25篇 |
预防医学 | 10908篇 |
眼科学 | 3846篇 |
药学 | 22660篇 |
39篇 | |
中国医学 | 5369篇 |
肿瘤学 | 13948篇 |
出版年
2024年 | 269篇 |
2023年 | 2010篇 |
2022年 | 3553篇 |
2021年 | 5812篇 |
2020年 | 5093篇 |
2019年 | 4822篇 |
2018年 | 4848篇 |
2017年 | 5351篇 |
2016年 | 5723篇 |
2015年 | 6094篇 |
2014年 | 10352篇 |
2013年 | 12686篇 |
2012年 | 10557篇 |
2011年 | 11918篇 |
2010年 | 9954篇 |
2009年 | 9777篇 |
2008年 | 10292篇 |
2007年 | 10100篇 |
2006年 | 8954篇 |
2005年 | 7962篇 |
2004年 | 6919篇 |
2003年 | 6166篇 |
2002年 | 5103篇 |
2001年 | 4440篇 |
2000年 | 3914篇 |
1999年 | 3358篇 |
1998年 | 3228篇 |
1997年 | 2914篇 |
1996年 | 2660篇 |
1995年 | 2293篇 |
1994年 | 1982篇 |
1993年 | 1697篇 |
1992年 | 1404篇 |
1991年 | 1222篇 |
1990年 | 1045篇 |
1989年 | 849篇 |
1988年 | 674篇 |
1987年 | 614篇 |
1986年 | 583篇 |
1985年 | 770篇 |
1984年 | 629篇 |
1983年 | 405篇 |
1982年 | 558篇 |
1981年 | 385篇 |
1980年 | 314篇 |
1979年 | 201篇 |
1978年 | 158篇 |
1977年 | 128篇 |
1976年 | 113篇 |
1975年 | 85篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
101.
目的探讨补骨脂素抗增生性瘢痕的作用机制。方法体外培养成纤维细胞,按随机数字表法分为正常组(培养正常成纤维细胞)、瘢痕组(培养增生性瘢痕成纤维细胞)、TGF-β1组(10 ng/ml TGF-β1处理增生性瘢痕成纤维细胞5 min^12 h)、Smurf2 RNA干扰组[Smad泛素化调节因子2(Smad ubiquitin regulatory factor2,Smurf2)siRNA转染增生性瘢痕成纤维细胞72 h]、补骨脂素组(10μmol/L补骨脂素处理增生性瘢痕成纤维细胞继续培养72 h)、补骨脂素+TGF-β1组(增生性瘢痕成纤维细胞加入补骨脂素培养72 h后加入TGF-β1培养6 h)。采用Western blot法检测Smurf2、α-平滑肌肌动蛋白(α-actin SMA,α-SMA)蛋白表达;RT-PCR法检测Ⅰ型胶原蛋白mRNA表达;ELISA法检测TGF-β1蛋白分泌。结果与正常组比较,瘢痕组Smurf2蛋白[(0.83±0.08)比(0.38±0.07)]表达增加(P<0.05);与瘢痕组比较,Smurf2 RNA干扰组TGF-β1[(2.2±0.18)比(4.2±0.47)]表达降低(P<0.05);TGF-β1组Smurf2[(0.71±0.06)比(0.42±0.04)]、α-SMA[(1.42±0.12)比(0.91±0.09)]蛋白表达增加(P<0.05),Ⅰ型胶原蛋白mRNA[(0.72±0.09)比(0.41±0.07)]表达增加(P<0.05);补骨脂素组Smurf2[(0.05±0.01)比(0.42±0.04)]、α-SMA[(0.71±0.07)比(0.91±0.09)]蛋白表达降低(P<0.05),Ⅰ型胶原蛋白mRNA表达[(0.12±0.04)比(0.41±0.07)]降低(P<0.05)。结论补骨脂素可能通过TGF-β1/Smurf2信号通路抑制α-SMA蛋白表达,从而降低Ⅰ型胶原蛋白表达,起到抑制瘢痕形成的作用。 相似文献
102.
Acute lung injury (ALI) is a major cause of sepsis-induced acute respiratory failure. Emodin has been considered to play a protective role for acute lung edema in cecal ligation and puncture (CLP)-induced sepsis model. In this study we aimed to investigate whether emodin could improve CLP-induced lung sepsis via regulating aquaporin (AQP) and tight junction (TJ), inflammatory factors, and pulmonary apoptosis. The results showed that sepsis-induced pulmonary pathological changes were significantly improved after emodin treatment. Emodin was found to upregulate AQP and TJ expression in the CLP model. Meanwhile, inflammatory cytokine release and pulmonary apoptosis was remarkably reduced after emodin treatment in lung sepsis. Our data demonstrated that emodin could suppresse inflammation, restore pulmonary epithelial barrier and reduce mortality in CLP-induced ALI, suggesting the potential therapeutic application of emodin in sepsis. 相似文献
103.
《Vaccine》2020,38(39):6141-6152
Influenza vaccination is considered the most valuable means to prevent and control seasonal influenza infections, which causes various clinical symptoms, ranging from mild cough and fever to even death. Among various influenza vaccine types, the inactivated subunit type is known to provide improved safety with reduced reactogenicity. However, there are some drawbacks associated with inactivated subunit type vaccines, with the main ones being its low immunogenicity and the induction of Th2-biased immune responses. In this study, we investigated the role of a single-stranded RNA (ssRNA) derived from the intergenic region in the internal ribosome entry site of the Cricket paralysis virus as an adjuvant rather than the universal vaccine for a seasonal inactivated subunit influenza vaccine. The ssRNA adjuvant stimulated not only well-balanced cellular (indicated by IgG2a, IFN-γ, IL-2, and TNF-α) and humoral (indicated by IgG1 and IL-4) immune responses but also a mucosal immune response (indicated by IgA), a key protector against respiratory virus infections. It also increases the HI titer, the surrogate marker of influenza vaccine efficacy. Furthermore, ssRNA adjuvant confers cross-protective immune responses against heterologous influenza virus infection while promoting enhanced viral clearance. Moreover, ssRNA adjuvant increases the number of memory CD4+ and CD8+ T cells, which can be expected to induce long-term immune responses. Therefore, this ssRNA-adjuvanted seasonal inactivated subunit influenza vaccine might be the best influenza vaccine generating robust humoral and cellular immune responses and conferring cross-protective and long-term immunity. 相似文献
104.
目的:探讨电子线对胰岛素生长因子-1家族蛋白表达的影响,为研究辐射对肝脏的早期损伤提供依据。方法:采用电子线照射小鼠,照射剂量为1、2、4 Gy,用Western blot法检测照射后12、48和72 h小鼠肝脏中胰岛素生长因子1受体(IGF-1R)、胰岛素生长因子结合蛋白1(IGFBP1)、胰岛素生长因子结合蛋白4(IGFBP4)和胰岛素生长因子1(IGF-1)蛋白表达水平的改变。结果:照射剂量为1 Gy时,与对照组相比,IGF-1蛋白在照射后48 h时表达增加,IGFBP1、IGFBP4和IGF1R蛋白的表达在照射后12、48和72 h均表达减少。照射剂量为2 Gy时,IGF-1和IGFBP4蛋白在照射后48 h时表达增加,其余时间点表达减少。IGFBP1蛋白在照射后12 h时表达增加,48和72 h时表达减少。IGF1R蛋白在照射后3个时间点均呈现为表达减少。照射剂量4 Gy时,肝脏中IGF-1、IGFBP1和IGFBP4蛋白均表达减少,IGF1R蛋白在照射后12 h时表达增加,48、72 h时均表达减少(均为P < 0.05)。结论:电子线照射后小鼠肝脏中胰岛素生长因子-1家族蛋白多以下调表达为主,与前期基因表达的结果相一致,有可能作为反映放射性工作人员早期肝脏损伤的生物标志物之一。 相似文献
105.
Zhengxian Huang Nan Xie Haichao Liu Yuehan Wan Yue Zhu Ming Zhang Yifan Tao Han Zhou Xiqiang Liu Jinsong Hou Cheng Wang 《Journal of oral pathology & medicine》2019,48(9):788-798
It has been suggested that tumour‐infiltrating lymphocytes (TILs) are associated with the progression of oral squamous cell carcinoma (OSCC). However, the prognostic value of TILs is inconclusive due to the heterogeneity of immune cells within the tumour microenvironment. In this meta‐analysis, we aimed to assess the prognostic value of TILs in OSCC. The PubMed, Cochrane, Embase, Scopus and Web of Science databases were searched up to April 20, 2019, and 33 studies were ultimately included in this meta‐analysis. Our pooled meta‐analysis showed that high infiltration of CD8+ TILs, CD45RO+ TILs and CD57+ TILs favoured better overall survival (OS). However, high infiltration of CD68+ macrophages and CD163+ macrophages was associated with poor prognosis in OSCC. These findings suggest that CD8+ TILs, CD45RO+ TILs, CD57+ TILs, CD68+ macrophages and CD163+ macrophages might serve as novel prognostic factors and therapeutic targets in OSCC. 相似文献
106.
ABSTRACT Tryptophan (Trp) is not only a nutrient enhancer but also has systemic effects. Trp metabolites signaling through the well-known aryl hydrocarbon receptor (AhR) constitute the interface of microbiome-gut-brain axis. However, the pathway through which Trp metabolites affect central nervous system (CNS) function have not been fully elucidated. AhR participates in a broad variety of physiological and pathological processes that also highly relevant to intestinal homeostasis and CNS diseases. Via the AhR-dependent mechanism, Trp metabolites connect bidirectional signaling between the gut microbiome and the brain, mediated via immune, metabolic, and neural (vagal) signaling mechanisms, with downstream effects on behavior and CNS function. These findings shed light on the complex Trp regulation of microbiome-gut-brain axis and add another facet to our understanding that dietary Trp is expected to be a promising noninvasive approach for alleviating systemic diseases. 相似文献
107.
《Journal of thoracic oncology》2021,16(9):1449-1460
Pulmonary immune-related adverse events represent rare but potentially severe side effects of immunotherapies. Diagnosis is often challenging, as symptoms and imaging features are not specific and may mimic other lung diseases, thus potentially delaying appropriate patient management. In this setting, an accurate imaging evaluation is essential for a prompt detection and correct management of these drug-induced lung diseases. The purpose of this article is to review the different types of pulmonary immune-related adverse events, describe their imaging characteristics on both high-resolution computed tomography and positron emission tomography/computed tomography and stress their underlying diagnostic challenge by presenting the mimickers. 相似文献
108.
109.
110.
OBJECTIVES: To assess the effectiveness and safety of additional bedtime H2‐receptor antagonists (H2RAs) in suppressing nocturnal gastric acid breakthrough (NAB) via a systematic review. METHODS: Eligible trials were identified by searching the Cochrane Central Register of Controlled Trials (CENTRAL) (Cochrane Library Issue 2, 2004), MEDLINE (January 1966–June 2004), EMBASE (January 1980–June 2004) and CINAHL (January 1982–June 2004). Additional hand‐searching was conducted on the proceedings of correlated conferences, eight important Chinese journals and references of all included trials. All randomized controlled trials evaluating H2RAs for the control of NAB were eligible for inclusion. The systematic review was conducted using methods recommended by The Cochrane Collaboration. RESULTS: Only two randomized crossover studies, comprising 32 participants, met the inclusion criteria. Because the design, dosage and duration of the treatments were different between the studies, it was not possible to conduct meta‐analysis. There were no consistent conclusions found between the two included studies in evaluating H2RAs for the control of NAB. CONCLUSIONS: No implications for practice at this stage can be concluded. Appropriately designed large‐scale randomized controlled trials with long‐term follow up are needed to determine the effects of additional bedtime H2RAs in suppressing NAB. 相似文献